archive-com.com » COM » E » ENDEAVOURVISION.COM

Total: 462

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • BIND Biosciences CEO Scott Minick and Founder Omid Farokhzad Win Ernst & Young New England Entrepreneur of the Year Award
    Board of California Pacific Medical Center through 2009 He received his postgraduate training in neurobiology at the Salk Institute an M B A from Northwestern University and a B A with Honors from the University of California at San Diego Omid Farokhzad M D is Associate Professor at Harvard Medical School and a physician scientist in the Department of Anesthesiology at Brigham and Women s Hospital He is a co founder of BIND Biosciences Selecta Biosciences and Blend Therapeutics Dr Farokhzad s research group is focused on developing novel nanotechnologies for medical applications He has pioneered the application of micro and nanotechnology for high throughput development and screening of targeted drug delivery systems for a myriad of clinical applications Dr Farokhzad has authored more than 80 papers and is an inventor of more than 65 issued and pending patents He completed his post doctoral clinical and research trainings respectively at the Brigham and Women s Hospital Harvard Medical School and the Massachusetts Institute of Technology in the laboratory of Dr Robert Langer He received his M D and M A from Boston University School of Medicine Across the United States hundreds of inspiring and innovative individuals were selected as Ernst Young Entrepreneur of the Year finalists Beginning in June winners in 26 regions are honored locally for their vision leadership and ability to grow the successful businesses that help sustain our economy These winners including Mr Minick and Dr Farokhzad will be eligible for the national awards to be presented by Ernst Young in Palm Springs in November About Ernst Young Entrepreneur Of The Year R Ernst Young Entrepreneur Of The Year is the world s most prestigious business award for entrepreneurs The unique award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision leadership and achievement As the first and only truly global award of its kind Entrepreneur Of The Year celebrates those who are building and leading successful growing and dynamic businesses recognizing them through regional national and global awards programs in more than 140 cities in more than 50 countries About BIND Biosciences BIND Biosciences is a clinical stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins TM BIND s Medicinal Nanoengineering TM platform enables the design engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites dramatically enhancing efficacy while minimizing toxicities BIND is developing a pipeline of novel Accurins that hold extraordinary potential to become best in class drugs and improve patient outcomes in the areas of oncology inflammatory diseases and cardiovascular disorders BIND s lead product candidate BIND 014 is currently in Phase 1 clinical testing in cancer patients and is designed to selectively target a surface protein upregulated in a broad range of solid tumors BIND also develops Accurins in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to

    Original URL path: http://www.endeavourvision.com/news-n157-c72-BIND+Biosciences+CEO+Scott+Minick+and+Fo.htm (2016-04-25)
    Open archived version from archive


  • BIND Biosciences Presents Clinical Data on BIND-014 Promising Anti-tumor Effects in Patients with Advanced or Metastatic Cancers
    which conventional docetaxel has minimal activity At all dose levels studied with 75 mg m2 reached to date BIND 014 was generally well tolerated with no new toxicities observed Dose escalation continues Strong translation of pharmacokinetic data from preclinical findings to Phase 1 clinical data with highly differentiated PK profile from conventional docetaxel and strong dose linearity across doses The clinical results are consistent with the preclinical findings that BIND 014 concentrates drug activity in the tumor resulting in improved efficacy We are very pleased with these data as our ongoing clinical study with BIND 014 lays a strong foundation to advance into Phase 2 development later this year In addition these data show the emerging potential of BIND 014 to be a significant new cancer therapy for patients by fundamentally changing the pharmacology of docetaxel allowing it to differentially concentrate in the tumors by up to ten fold as shown in our preclinical models for better clinical efficacy across multiple cancers including those in which conventional docetaxel has minimal activity said Scott Minick President and Chief Executive Officer of BIND Biosciences BIND 014 is the clinical validation of BIND s Accurin technology platform and marks an important milestone for the field of nanomedicine BIND and most importantly patients The Phase 1 study has an ascending intravenous dose design The objectives of the study are to determine the safety tolerability and maximum tolerated dose of BIND 014 and to assess preliminary evidence of antitumor activity This clinical study is being conducted at the Virginia G Piper Cancer Center at Scottsdale Healthcare in Scottsdale Arizona in collaboration with the Translational Genomics Research Institute and the Scottsdale Healthcare Research Institute the Karmanos Cancer Institute in Detroit Michigan and Marin Specialty Care in Greenbrae California About BIND 014 BIND 014 is a programmable nanomedicine that combines a targeting ligand and a therapeutic nanoparticle BIND 014 contains docetaxel a proven cancer drug which is approved in major cancer indications including breast prostate and lung encapsulated in FDA approved biocompatible and biodegradable polymers BIND 014 is targeted to prostate specific membrane antigen PSMA a cell surface antigen abundantly expressed on the surface of cancer cells and on new blood vessels that feed a wide array of solid tumors In preclinical cancer models BIND 014 was shown to deliver up to ten fold more docetaxel to tumors than an equivalent dose of conventional docetaxel The increased accumulation of docetaxel at the site of disease translated to marked improvements in antitumor activity and tolerability BIND 014 is currently in Phase 1 human clinical testing in patients with advanced or metastatic solid tumor cancers NCT01300533 The early development of BIND 014 was funded in part by the National Cancer Institute and the U S National Institutes of Standards and Technology NIST under its Advanced Technology Program ATP About BIND Biosciences BIND Biosciences is a clinical stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM BIND s Medicinal NanoengineeringTM platform enables the

    Original URL path: http://www.endeavourvision.com/news-n150-c72-BIND+Biosciences+Presents+Clinical+Data+.htm (2016-04-25)
    Open archived version from archive

  • BIND Announces New $47.25 Million Financing To Accelerate Multi-Product Pipeline
    with RUSNANO additional new investors and full support by BIND s existing investors including Polaris Venture Partners Flagship Ventures ARCH Venture Partners NanoDimension DHK Investments and EndeavourVision In addition to the Series D round BIND has additional funding up to 25 25 million for strategic activities in Russia A key use of the proceeds of this funding will be the advancement of BIND s lead product candidate BIND 014 through clinical studies In addition the proceeds of this financing will be used to accelerate BIND s pipeline including the initiation of a second clinical program for an internal drug candidate from BIND s platform of targeted therapeutics BIND s Accurin therapeutics show enormous promise to be best in class drugs for cancer and other diseases by overcoming a key challenge in drug development targeting drugs to the site of disease while reducing the side effects on healthy cells said Professor Robert Langer David H Koch Institute Professor at the Massachusetts Institute of Technology a recipient of the US National Medal of Science and a founder and Director of BIND Biosciences Led by a strong team and advancing truly breakthrough therapeutics BIND has been impressive in accomplishing its scientific clinical and business milestones and we believe this funding will enable BIND to continue to demonstrate the tremendous value of its Accurin drug candidates About RUSNANO RUSNANO was established in March 2011 as an open joint stock company created through reorganization of the state corporation Russian Corporation of Nanotechnologies RUSNANO s mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit The Government of the Russian Federation owns 100 percent of the shares in RUSNANO Anatoly Chubais is CEO and chairman of the Executive Board of RUSNANO Work to establish nanotechnology infrastructure and training for nanotechnology specialists formerly conducted by the Russian Corporation of Nanotechnologies has been entrusted to the Fund for Infrastructure and Educational Programs a non commercial fund also established through reorganization of the Russian Corporation of Nanotechnologies More information about RUSNANO may be found at http www rusnano com Section aspx Show 17872 About BIND Biosciences BIND is a clinical stage biopharmaceutical company developing a new class of highly selective targeted therapeutics called AccurinsTM Accurins are designed to accumulate selectively at the site of disease dramatically enhancing efficacy while minimizing toxicities Using its Medicinal NanoengineeringTM platform BIND is developing a pipeline of novel Accurins that hold extraordinary potential to become best in class drugs and improve patient outcomes in the areas of oncology inflammatory diseases and cardiovascular disorders BIND s lead product candidate BIND 014 is currently in Phase 1 clinical testing in cancer patients and is designed to selectively target a surface protein upregulated in a broad range of solid tumors BIND also develops Accurins in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to achieve their full potential and to utilize selective targeting to transform the performance of important existing drug products BIND

    Original URL path: http://www.endeavourvision.com/news-n126-c72-BIND+Announces+New+%2447.25+Million+Fina.htm (2016-04-25)
    Open archived version from archive

  • BIND Biosciences Receives 2011 Edison Award
    platform and organization to make revolutionary drugs for important human diseases said Scott Minick BIND s CEO Our technology has the potential to create targeted therapeutics across a range of drug classes including peptides proteins small molecules and siRNA By complementing conventional medicinal chemistry approaches BIND s targeted nanoparticle platform has demonstrated the potential to overcome many significant drug development challenges About The Edison Awards The Edison Awards recognize the persistence and excellence Thomas Edison personified qualities which have allowed America to remain in the forefront of innovation creativity and ingenuity in the global economy The Edison Awards are granted under the aegis of the Thomas Edison Papers at Rutgers University a globally recognized research network dedicated to the study of innovation and its application in the 21st century For more information about The Edison Awards visit www edisonawards com About BIND Biosciences BIND Biosciences Inc is a biopharmaceutical company leveraging its proprietary Medicinal Nanoengineering platform to produce best in class drugs BIND s platform enables the design engineering and manufacturing of targeted nanoparticle therapeutics with unprecedented control over drug PK biodistribution and cell or tissue specific targeting Medicinal Nanoengineering complements medicinal chemistry to enable predictable cost effective and rapid development of breakthrough products with superior efficacy and safety profiles Product opportunities include enabling or expediting the development of pipeline molecules as well as improving performance expanding indications or life cycle extension for mid and late stage products BIND s initial product development efforts are in the areas of oncology inflammatory diseases and cardiovascular disorders BIND s lead program BIND 014 targets a surface protein upregulated in a broad range of solid tumors BIND 014 is currently undergoing Phase I clinical testing in cancer patients BIND is backed by leading venture capital firms Polaris Venture Partners Flagship Ventures ARCH Venture Partners NanoDimension DHK Investments and EndeavourVision For more information please visit the company s web site at www bindbio com Contacts BIND Biosciences Andrea Franz 617 491 3400 afranz bindbio com back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project but it is more about extending your core team Thus it is about partnering with those who are great to work with and are team players Those who understand your business and embrace your vision Those who know how to challenge your execution and to bring value This is why I recommend Endeavour Vision team to entrepreneurs looking for funding Dr

    Original URL path: http://www.endeavourvision.com/news-n109-c72-BIND+Biosciences+Receives+2011+Edison+Aw.htm (2016-04-25)
    Open archived version from archive

  • BIND Biosciences named one of MIT's Technology Review 2011 TR50 - second year in a row
    value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project but it is more about extending your core team Thus it is about partnering with those who are great to work with and are team players Those who understand your business and embrace your vision Those who know how to challenge your execution and to bring value This is why I recommend Endeavour Vision team to entrepreneurs looking for funding Dr Georges Karam co Founder President CEO Sequans With Endeavour Vision we have been able to establish at fast speed the personal trust level needed and also come to terms very quick They are highly professional partners and support us in every possible manner Christian Lindner Co Founder and CEO Retailo AG We wanted a Venture Capital investor who was prepared to share our vision to create a global European company The quality of their track record the way they are helping us take our company to the next level and the pure scale of their ambition make them a pleasure to work with Boris Saragaglia CEO Spartoo com Endeavour Vision s team brought an in depth knowledge of our field highlighted by impressive and thorough 360 due diligence the long term perspective required to build substantial companies outstanding experience of bringing venture to financial success and an uncommon sense for team work This

    Original URL path: http://www.endeavourvision.com/news-n108-c72-BIND+Biosciences+named+one+of+MIT%27s+Te.htm (2016-04-25)
    Open archived version from archive

  • BIND Biosciences featured in the London Times
    them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project but it is more about extending your core team Thus it is about partnering with those who are great to work with and are team players Those who understand your business and embrace your vision Those who know how to challenge your execution and to bring value This is why I recommend Endeavour Vision team to entrepreneurs looking for funding Dr Georges Karam co Founder President CEO Sequans With Endeavour Vision we have been able to establish at fast speed the personal trust level needed and also come to terms very quick They are highly professional partners and support us in every possible manner Christian Lindner Co Founder and CEO Retailo AG We wanted a Venture Capital investor who was prepared to share our vision to create a global European company The quality of their track record the way they are helping us take our company to the next level and the pure scale of their ambition make them a pleasure to work with Boris Saragaglia CEO Spartoo com Endeavour Vision s team brought an in depth knowledge of our field highlighted by impressive and thorough 360 due diligence the long term perspective required to build substantial companies outstanding experience of bringing venture to financial success and an uncommon sense for team work This is smart money at its best Jacques

    Original URL path: http://www.endeavourvision.com/news-n107-c72-BIND+Biosciences+featured+in+the+London+.htm (2016-04-25)
    Open archived version from archive

  • BIND Biosciences Initiates Phase 1 Clinical Study of BIND-014
    Taxotere which is approved in major cancer indications including breast prostate and lung BIND 014 is targeted to prostate specific membrane antigen PSMA a cell surface antigen abundantly expressed on the surface of cancer cells and on new blood vessels that feed a wide array of solid tumors In preclinical cancer models BIND 014 was shown to deliver up to 20 times more docetaxel to tumors than an equivalent dose of Taxotere The increased accumulation of docetaxel at the site of disease translated to marked improvements in antitumor activity and tolerability BIND 014 is currently in Phase 1 human clinical testing in cancer patients This first of its kind human study stems from BIND s previously published non human studies in several peer reviewed scientific journals The development of BIND 014 was funded in part by the National Cancer Institute and the U S National Institutes of Standards and Technology NIST under its Advanced Technology Program ATP About BIND Biosciences BIND Biosciences Inc is a biopharmaceutical company leveraging its proprietary Medicinal Nanoengineering platform to produce best in class drugs to provide significant improvement in the treatment of patients with serious diseases BIND s platform enables the design engineering and manufacturing of therapeutic targeted nanoparticles with unprecedented control over drug pharmacokinetics biodistribution and cell or tissue specific targeting Medicinal Nanoengineering complements medicinal chemistry to enable predictable cost effective and rapid development of nanoparticle therapeutics with superior efficacy and safety profiles Product opportunities include enabling or expediting the development of pipeline molecules as well as improving performance expanding indications or life cycle extension for mid and late stage products BIND s initial product development efforts are in the areas of oncology cardiovascular disorders inflammatory disease and RNAi therapeutics BIND was founded in 2006 by two pioneers in the field of therapeutic targeted nanoparticles Drs Robert Langer and Omid Farokhzad BIND is backed by leading venture capital firms Polaris Venture Partners Flagship Ventures ARCH Venture Partners NanoDimension DHK Investments and Endeavour Vision For more information please visit the company s web site at www bindbio com www bindbio com About the Virginia G Piper Cancer Center at Scottsdale Healthcare The Virginia G Piper Cancer Center at Scottsdale Healthcare opened in 2001 as the first cancer center in the greater Phoenix area offering comprehensive cancer care and research through Phase I clinical trials diagnosis treatment prevention and support services in collaboration with leading researchers and community oncologists Scottsdale Healthcare is the nonprofit parent organization of the Scottsdale Healthcare Osborn Medical Center Scottsdale Healthcare Shea Medical Center and Scottsdale Healthcare Thompson Peak Hospital Virginia G Piper Cancer Center at Scottsdale Healthcare Scottsdale Healthcare Research Institute and Scottsdale Healthcare Foundation For more information visit www shc org www shc org About TGen The Translational Genomics Research Institute TGen is a non profit organization dedicated to conducting groundbreaking research with life changing results Research at TGen is focused on helping patients with diseases such as cancer neurological disorders and diabetes TGen is on the cutting edge of

    Original URL path: http://www.endeavourvision.com/news-n94-c72-BIND+Biosciences+Initiates+Phase+1+Clini.htm (2016-04-25)
    Open archived version from archive

  • BIND Biosciences Secures $12.4 Million Financing
    important therapeutic products based on the company s proprietary technology said Eric Milledge Venture Partner of Endeavour Vision and former Group Chairman at Johnson Johnson We believe that BIND s exciting platform has the potential to produce best in class products based on proven drugs and promising drug candidates The company also has a very strong foundation of broad intellectual property combined with scalable manufacturing and a team with an outstanding track record About BIND Biosciences BIND Biosciences Inc is a biopharmaceutical company leveraging its proprietary Medicinal Nanoengineering platform to produce best in class drugs to provide significant improvement in the treatment of patients with serious diseases BIND s platform enables the design engineering and manufacturing of therapeutic targeted nanoparticles with unprecedented control over drug pharmacokinetics biodistribution and cell or tissue specific targeting Medicinal Nanoengineering complements medicinal chemistry to enable predictable cost effective and rapid development of breakthrough products with superior efficacy and safety profiles Product opportunities include enabling or expediting the development of pipeline molecules as well as improving performance expanding indications or life cycle extension for mid and late stage products BIND s initial product development efforts are in the areas of oncology cardiovascular disorders inflammatory disease and RNAi therapeutics BIND s lead program BIND 014 targets a surface protein upregulated in solid tumors and is planned to enter clinical development in 2H 2010 BIND was founded in 2006 by two pioneers in the field of therapeutic targeted nanoparticles Dr Robert Langer MIT David H Koch Institute Professor and Dr Omid Farokhzad Harvard Medical School Associate Professor BIND is backed by leading venture capital firms Polaris Venture Partners Flagship Ventures ARCH Venture Partners NanoDimension DHK Investments and Endeavour Vision For more information please visit the company s web site at www bindbio com About Endeavour Vision Endeavour Vision combines a team of experienced venture capital professionals who have collectively invested in over 80 companies in 12 countries in both the Life Sciences and Information Communication Technology sectors since 1989 The firm invests in early stage companies which have the potential to become global leaders Past investments in Life Sciences by Endeavour Vision professionals include Actelion SWX ATLN Axovan acquired by Actelion and Endoart acquired by Allergan NYSE AGN For more information please visit www endeavourvision com Contacts BIND Biosciences Inc Andrea Franz Tel 617 491 3400 afranz bindbio com Media Kathryn Morris The Yates Network Tel 845 635 9828 kathryn theyatesnetwork com back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider

    Original URL path: http://www.endeavourvision.com/news-n82-c72-BIND+Biosciences+Secures+%2412.4+Million.htm (2016-04-25)
    Open archived version from archive



  •